Retinoid Receptor Alpha and Beta Expression in Serous Ovarian Tumors
Retinoid Receptor Alpha and Beta Expression in Serous Ovarian Tumors
复制标题
类维生素A受体α和β在浆液性卵巢肿瘤中的表达
作者：
Alexandros Daponte;E. Kostopoulou;I. Chiotoglou;P. Vanakara;M. Minas;Maria Nakou;A. Kallitsaris;Panagoula Kollia;George K. Koukoulis;Ioannis E. Messinis
采用免疫组化和Western blotting法检测正常卵巢、浆液性囊腺瘤（n = 20）、浆液性交界性卵巢癌（n = 14）和浆液性卵巢癌（n = 47）中维甲酸受体α（RAR α）和β（RAR β）以及雌激素受体α（ER α）的表达，并将其与肿瘤的分期、分级、无进展生存期（PFS）和生存期进行相关性分析。RAR α在良性囊腺瘤、交界性、低分期和晚期肿瘤中表达增加（p <0.001）。在III期G3浆液性癌中，RAR α表达增加是与一线化疗（紫杉醇和卡铂）的较低化学反应和较短PFS相关的独立预后因素（p <0.002）。RAR β和ER α表达与RAR α肿瘤特征或PFS和生存无关。
The expression of retinoid acid receptors α (RARα) and β (RARβ) and estrogen receptor α (ERα) was assessed by immunohistochemistry and Western blotting in normal ovaries, serous cystadenoma (n = 20), serous borderline (n = 14), and serous ovarian cancer (n = 47) and was correlated in cancer cases with stage, grade, progress-free survival (PFS), and survival. RARα was increasingly expressed in benign cystadenomas, borderline, and low-stage and advanced-stage neoplasms (p < 0.001). In stage III, G3 serous carcinoma, increased RARα expression was an independent prognostic factor associated with lower chemoresponse to first-line chemotherapy (taxol and carboplatin) and shorter PFS (p < 0.002).RARβ and ERα expression did not correlate with RARα tumor characteristics or PFS and survival.
影响因子：
14
作者：
Bamberg, Fabian;Marcus, Roy P.;Theisen, Daniel
通讯作者：
Theisen, Daniel
影响因子：
6.2
作者：
Soung, Do Y.;Talebian, Laleh;Matheny, Christina J.;Guzzo, Rosa;Speck, Maren E.;Lieberman, Jay R.;Speck, Nancy A.;Drissi, Hicham
通讯作者：
Drissi, Hicham
DOI：
10.1093/jnci/91.21.1847
发表时间：
1999-11-03
期刊：
JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子：
--
作者：
Veronesi, U;De Palo, G;Sporn, MB
通讯作者：
Sporn, MB